Presentation
17 March 2023 Multispectral imaging quantifies available immune-inhibitory receptor concentrations for therapeutic binding of anti-PD-1 checkpoint inhibitors
Author Affiliations +
Abstract
Immune checkpoint inhibitors (ICIs) are among the most effective classes of cancer immunotherapies yet only a small minority of patients derive clinical benefit. We are investigating the use of multi-spectral paired-agent imaging (mPAI) to quantify available PD-1 and PD-L1 receptor concentrations for the therapeutic binding of anti-PD-1 checkpoint inhibitors.
Conference Presentation
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Divya Ravi, Abdibaset A. Bare, Emma M. Cammack, Veronica C. Torres, and Kimberley S Samkoe "Multispectral imaging quantifies available immune-inhibitory receptor concentrations for therapeutic binding of anti-PD-1 checkpoint inhibitors", Proc. SPIE 12357, Visualizing and Quantifying Drug Distribution in Tissue VII, 123570H (17 March 2023); https://doi.org/10.1117/12.2650637
Advertisement
Advertisement
KEYWORDS
Receptors

Multispectral imaging

Tumors

Tissues

Cancer

Flow cytometry

In vivo imaging

Back to Top